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Strengths and limitations of this study
 ► The pathway simulation and methodology present-
ed enhances the national clinical audit by providing 
insight into the interhospital variation in use and 
speed of thrombolysis.
 ► The methods allow reasonable thrombolysis targets 
to be set that are tailored to local stroke patient pop-
ulation characteristics.
 ► The methods (with code published in full) may be 
applied using open source software and may be 
applied at scale while providing tailored insight for 
individual hospitals.
 ► The methods are limited to information gathered 
in the national clinical audit for stroke and do not 
include use of advanced imaging techniques for se-
lection of patients for thrombolysis.
AbStrACt
Objective To evaluate the application of clinical pathway 
simulation in machine learning, using clinical audit data, in 
order to identify key drivers for improving use and speed of 
thrombolysis at individual hospitals.
Design Computer simulation modelling and machine 
learning.
Setting Seven acute stroke units.
Participants Anonymised clinical audit data for 7864 
patients.
results Three factors were pivotal in governing 
thrombolysis use: (1) the proportion of patients with a 
known stroke onset time (range 44%–73%), (2) pathway 
speed (for patients arriving within 4 hours of onset: per-
hospital median arrival-to-scan ranged from 11 to 56 min; 
median scan-to-thrombolysis ranged from 21 to 44 min) 
and (3) predisposition to use thrombolysis (thrombolysis 
use ranged from 31% to 52% for patients with stroke 
scanned with 30 min left to administer thrombolysis). 
A pathway simulation model could predict the potential 
benefit of improving individual stages of the clinical 
pathway speed, whereas a machine learning model 
could predict the benefit of ‘exporting’ clinical decision 
making from one hospital to another, while allowing 
for differences in patient population between hospitals. 
By applying pathway simulation and machine learning 
together, we found a realistic ceiling of 15%–25% use of 
thrombolysis across different hospitals and, in the seven 
hospitals studied, a realistic opportunity to double the 
number of patients with no significant disability that may 
be attributed to thrombolysis.
Conclusions National clinical audit may be enhanced 
by a combination of pathway simulation and machine 
learning, which best allows for an understanding of key 
levers for improvement in hyperacute stroke pathways, 
allowing for differences between local patient populations. 
These models, based on standard clinical audit data, may 
be applied at scale while providing results at individual 
hospital level. The models facilitate understanding of 
variation and levers for improvement in stroke pathways, 
and help set realistic targets tailored to local populations.
IntrODuCtIOn
NHS England describes clinical audit as 
a way of identifying whether healthcare is 
being provided in accordance with agreed 
standards and where improvements could 
be made to improve outcomes for patients.1 
Audits may be local or national. In England 
the Healthcare Quality Improvement Part-
nership (HQIP), on behalf of the National 
Health Service (NHS), is responsible for over-
seeing and commissioning more than 30 clin-
ical audits, which form the National Clinical 
Audit Programme.2 These collect and analyse 
data supplied by local clinicians.
The national audit covering stroke is the 
Sentinel Stroke National Audit Programme 
(SSNAP).3 Stroke is a leading cause of death 
and disability worldwide, with an estimated 
5.9 million deaths and 33 million stroke 
survivors in 2010.4 In England, Wales and 
Northern Ireland, 85 000 people are hospi-
talised with stroke each year,5 and stroke is 
ranked third as a cause of disability-adjusted 
life years in the UK over the last 25 years.6
SSNAP collects longitudinal data on the 
processes and outcomes of stroke care up to 
6 months poststroke for more than 90% of 
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stroke admissions to acute hospitals in England, Wales 
and Northern Ireland. Every year data from approxi-
mately 85 000 patients are collected. SSNAP publishes 
quarterly and yearly analysis of results on its website.3
SSNAP audit data are used for a wide range of research, 
such as investigating how the type of stroke affects clin-
ical decisions,7 how socioeconomic factors influence risk 
of stroke, care received and outcomes,8 and how care 
processes may vary by time of day and day of week.9
In this paper we report on the potential of using simu-
lation and machine learning to enhance the output of the 
SSNAP clinical audits. In particular we focus on the acute 
stroke pathway and clinical decision making leading to 
the use of thrombolysis for the treatment of acute stroke, 
the only licensed drug treatment for acute stroke and one 
that is critically time-dependent,10 with little or no benefit 
after 4.5 hours from stroke onset. The population benefit 
from thrombolysis has been limited by slow uptake of the 
treatment and in-hospital delays to the administration of 
thrombolysis.11–13
In England, Wales and Northern Ireland, 11.1% of 
patients with confirmed acute stroke receive thrombol-
ysis, but use in individual acutely admitting stroke teams 
varies from 0% to 24.5%.5 The lowest 10% of acutely 
admitting stroke teams administer thrombolysis to fewer 
than 5.9% of patients, whereas the top 10% administer 
thrombolysis to more than 16.7%. Time from arrival to 
thrombolysis (‘door-to-needle’) also varies significantly. 
The fastest 10% of hospitals have door-to-needle times 
of 40 min or less, whereas the slowest 10% have door-
to-needle times of 85 min or more.5 There is therefore 
considerable variation between hospitals in the use and 
speed of thrombolysis for patients with acute stroke.
The model described here has three components: (1) 
a clinical pathway model, (2) a clinical outcome model 
based on the speed and number of patients treated with 
thrombolysis, and (3) a clinical decision-making model 
based on machine learning.
Analysis of patient pathway data coupled with pathway 
modelling has previously allowed investigation and 
improvement of thrombolysis use in individual hospi-
tals, increasing both the number of patients treated and 
reducing door-to-needle times.14 15 These models have 
usually focused on the speed of the acute stroke pathway 
from arrival at hospital to giving thrombolysis, and 
have been tailored to use data available at an individual 
hospital.14
Pathway modelling based on simulating process steps 
allows for good simulation of the speed of the stroke 
pathway, but cannot easily model differences in clinical 
decision making. We were interested in testing whether a 
model could dissect out the variation in thrombolysis rate 
that is dependent on differences in patient populations 
(eg, age or stroke severity) in different hospitals, from the 
differences that are dependent on the culture of decision 
making at different hospitals (eg, more cautious vs more 
aggressive clinical decision making). A variety of machine 
learning techniques now exist,16 which are able to make 
good predictions on pre-existing multidimensional data 
over a binary or categorical outcome variable (such as 
whether a patient receives thrombolysis or not). These 
have the potential to add modelling of clinical decision 
making to a model of the acute stroke pathway, with the 
aim of predicting what decision (to thrombolyse or not) 
would be made for the same patient in different hospitals. 
Models may also be trained on a reference standard set of 
hospitals (regarded as centres of clinical excellence) and 
use of thrombolysis for any patient predicted using that 
‘benchmark clinical decision-making model’.
We have chosen to combine these three components 
of pathway, clinical outcome and clinical decision-making 
modelling as these provide a more powerful and informa-
tive model than can be achieved by any single technique.
The aim of our work was to extend previous work on 
stroke thrombolysis pathway simulation in three signif-
icant ways: (1) to create a generic stroke thrombolysis 
pathway simulation model that could be easily applied to 
all hospitals in SSNAP; (2) extend the analysis to include 
factors other than door-to-needle times, with special focus 
on differences in clinical decision making as analysed 
and modelled with machine learning techniques; and (3) 
develop modelling framework that is open source and 
fast enough to run routine analysis at national level.
MethODS
Data
Anonymous SSNAP data were obtained from seven hospi-
tals in England for patients with confirmed stroke over 
a period of 2 years (2013–2014) for each hospital. These 
data were secondary data, collected during routine care. 
No patient identifiable information was obtained.
For the pathway simulation model, the data set 
contained 7871 patient records with complete data 
for 12 parameters regarding their characteristics and 
time-stamped pathway location. These data represent 
out-of-hospital onset of stroke (which accounts for 94% 
of all admissions recorded in the SSNAP data used).
For machine learning, only those patients with a 
completed National Institutes of Health Stroke Scale and 
who had at least 30 min left to give thrombolysis were used 
(1862 patients). As a precaution to maintain complete 
patient anonymity, 17 patients aged under 40 had their 
age censored to 40, and 6 patients over the age of 100 had 
their age censored to 100.
Pathway simulation model
The pathway simulation model (shown schematically 
in figure 1) simulates the flow of patients through the 
acute stroke pathway to the point of thrombolysis. Model 
parameters were set for each hospital by sampling from 
distributions derived from anonymous data retrieved 
from SSNAP for each hospital. The model parameters, 
distribution types and the values used are given in the 
online supplement.
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Figure 1 Modelled sequence of steps of the emergency stroke pathway leading to thrombolysis.
Figure 2 Validation of the pathway simulation model, 
comparing actual with modelled (predicted) thrombolysis 
based on random sampling of all data. Samples were 600 
points (representing typical acute stroke unit admission 
numbers) chosen randomly with resampling from patients 
given or not given thrombolysis to create a range of 
thrombolysis use examples. Points show mean predicted 
thrombolysis use from 100 runs, with each run modelling 
1 year.
For a patient to receive thrombolysis, they must meet 
the following criteria: (1) stroke onset time known, (2) 
arrival at hospital within 4 hours of stroke onset, (3) have 
an ischaemic stroke and judged to be eligible for throm-
bolysis, and (4) be within the allowed thrombolysis time 
window (4.5 hours and 3 hours onset-to-treatment time 
for patients aged under 80 and 80+, respectively), when 
summing the process step times in the model. If a patient 
receives thrombolysis in the model, then the probability 
of an additional good outcome (Modified Rankin Scale 
0–1, no significant disability and able to carry out all usual 
activities) due to use of thrombolysis is calculated from 
the onset-to-treatment time and is based on the meta-anal-
ysis by Emberson et al.10
The pathway simulation model was validated by (1) 
random bootstrap sampling of 100 groups of 600 patients 
with varying overall thrombolysis use, comparing actual 
with predicted thrombolysis use, and (2) comparing 
actual and predicted thrombolysis use and speed across 
the seven hospitals.
Clinical decision model (machine learning)
The clinical decision model aims to replicate the decision 
to give or not give treatment with thrombolysis for any 
given patient at any given hospital.
The model predicts whether an individual patient 
would receive thrombolysis or not from a set of 50 
parameters defining the patient’s characteristics, clin-
ical well-being and hospital attended. Following a 
comparison of methods, a random forests method was 
chosen (see online supplement for a list of all features 
used and a comparison of different machine learning 
models).
This model is intended to make decisions based only on 
clinical presentation, assuming that there is time to give 
thrombolysis. Patients were included if they had been 
scanned with 30 min left to give thrombolysis (allowing 
4.5 hours and 3 hours from onset to treatment for patients 
aged under 80 and 80+, respectively).
The machine learning model was validated using strat-
ified tenfold validation, where the data are split into 10 
subsets, and the model run 10 times (with each model 
run using 9 subsets for training and 1 subset held back for 
testing, with all data present in a test subset once and only 
once). All machine learning methods and validation were 
coded in Python using the SciKit Learn machine learning 
library.17
Patient and public involvement
Through this study we have used a panel of four to five 
stroke survivors or carers of stroke survivors. These were 
recruited through the National Institute for Health 
Research PenCLAHRC (The National Institute for Health 
Research Collaboration in Applied Health Research and 
Care South West Peninsula) Patient and Public Involve-
ment group. These have met three times during the 
course of this project to help review aims, results and 
future plans.
reSultS
Pathway simulation
The pathway simulation model was validated by (1) 
random bootstrap sampling varying overall thrombolysis 
use, comparing actual with predicted thrombolysis use, 
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Table 1 Comparison of actual versus modelled hospital performance
Hospital 1 2 3 4 5 6 7
Actual thrombolysis (%) 13.7 8.0 8.4 7.0 8.5 14.5 9.2
Model thrombolysis (%) 12.9 7.1 7.6 6.3 8.1 12.0 8.0
Actual onset to thrombolysis (hours) 2.4 2.6 2.9 2.5 2.3 2.5 2.5
Model onset to thrombolysis (hours) 2.6 2.6 3.0 2.6 2.7 2.6 2.5
Table 2 Predicted thrombolysis use and clinical benefit across all modelled hospitals (1–7)
Hospital Base A B C ABC
Thrombolysis use (%) 1 12.7 (0.3) 17.6 (0.3) 13.9 (0.3) 14.6 (0.3) 21.5 (0.3)
2 7.0 (0.2) 10.4 (0.3) 10.8 (0.2) 10.0 (0.3) 23.4 (0.3)
3 7.7 (0.2) 9.7 (0.2) 11.9 (0.2) 10.9 (0.2) 21.7 (0.3)
4 6.2 (0.2) 6.8 (0.2) 11.2 (0.2) 11.3 (0.3) 20.7 (0.3)
5 7.9 (0.3) 10.4 (0.3) 10.0 (0.3) 13.2 (0.4) 22.1 (0.5)
6 12.3 (0.3) 16.3 (0.4) 14.5 (0.4) 12.7 (0.3) 20.2 (0.4)
7 8.0 (0.2) 9.4 (0.2) 14.0 (0.3) 10.8 (0.2) 22.5 (0.3)
Additional good outcomes per 1000 admissions 1 11.1 (0.2) 17.2 (0.3) 12.2 (0.2) 12.8 (0.3) 21.0 (0.3)
2 6.1 (0.2) 10.2 (0.3) 9.3 (0.2) 8.6 (0.2) 23.0 (0.4)
3 6.5 (0.2) 10.1 (0.2) 10.0 (0.2) 9.1 (0.2) 22.5 (0.3)
4 5.4 (0.2) 6.7 (0.2) 9.8 (0.2) 9.9 (0.2) 20.0 (0.3)
5 7.0 (0.3) 10.8 (0.4) 8.7 (0.3) 11.8 (0.4) 23.1 (0.5)
6 10.6 (0.3) 16.0 (0.4) 12.5 (0.3) 11.0 (0.3) 19.9 (0.4)
7 7.1 (0.2) 9.5 (0.3) 12.4 (0.2) 9.6 (0.2) 22.9 (0.3)
Data show (base) model based on parameters derived from current performance; (A) arrival-to-scan and scan-to-thrombolysis both fixed 
at 15 min (with no variation in either time); (B) judged to be eligible for thrombolysis fixed at 60%; (C) onset time known fixed at 77%; and 
combinations of the above. Results show mean and ±95% confidence limits (100 runs).
and (2) comparing actual and predicted thrombolysis use 
and speed across the seven hospitals.
In the random sampling (figure 2), 600 patients 
(typical of an acute stroke unit) were sampled randomly, 
with resampling from either the thrombolysis group or 
the no-thrombolysis group to give varying samples with 
an overall thrombolysis use rate of 1%–25%. There were 
100 model runs performed. The model showed very 
good correlation (R2=0.99) between actual and predicted 
values, although the model slightly underpredicted actual 
thrombolysis use, with predicted thrombolysis being, on 
average, 89% that of actual thrombolysis use.
The model was further validated by comparing 
modelled (predicted) use of thrombolysis with actual use 
of thrombolysis (table 1). Actual use of thrombolysis was 
based on modelling a 1-year period with replicates of 100 
runs (each with different random number seeds) in order 
to determine expected year-to-year variation. The model 
showed very good correlation (R2=0.96) between actual 
and predicted values, although the model again slightly 
underpredicted actual thrombolysis use, with predicted 
thrombolysis being, on average, 90% that of actual throm-
bolysis use.
The difference between predicted and actual throm-
bolysis use is largely explained by the observation that 8% 
of thrombolysis in the SSNAP data set was given outside 
of the assumed allowable times for thrombolysis in the 
model; the model applies a stricter time cut-off than clini-
cians allow in reality.
The model was run with various ‘what-if?’ scenarios for 
each of the seven hospitals (table 2).
 ► Base case: model based on parameters derived frm 
current hospital-specific performance
 ► Scenario B: 60% of patients with ischaemic stroke 
scanned with 30 min left to treat receive thrombolysis 
(an analysis of ECASS-3/IST-3 results concluded that 
591 out of 992, or 60%, of patients with ischaemic 
stroke arriving within 4 hours of stroke onset were 
suitable for thrombolysis18).
 ► Scenario C: onset time known fixed at 77% (national 
SSNAP upper quartile for year 2015/20165).
 ► Combination of above.
In order to achieve the greatest improvement in throm-
bolysis use in each of the seven hospitals, for two hospi-
tals (hospitals 1 and 6) it would be best to improve the 
speed of the pathway, for two hospitals (hospitals 4 and 
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Table 3 Actual and predicted thrombolysis use (for patients 
scanned with time left to thrombolysis) if the decision to 
give thrombolysis is based on decisions made by a random 
forest model trained at different hospitals
Actual thrombolysis use by hospital
1 2 3 4 5 6 7
52 35 48 33 49 44 31
Predicted thrombolysis use at each hospital depending on 
which hospital is used to train the decision model and which 
hospital patients actually attend
Hospitals patients actually attend
1 2 3 4 5 6 7
Hospital 
used to train 
model
1 52 42 58 50 67 57 45
2 48 35 55 36 46 37 29
3 53 38 48 46 58 41 34
4 40 28 48 33 52 29 26
5 50 36 50 40 49 45 37
6 49 32 55 44 59 44 39
7 42 23 42 31 50 36 31
The columns represent the likely difference in thrombolysis use due 
to differences in decision making.
5) it would be best to improve determination of stroke 
onset time, and for three (hospitals 2, 3 and 7) it would 
be best to judge more patients as eligible for thrombol-
ysis for those scanned with time left to treat. If a priority 
is to maximise clinical outcome, then for four hospitals 
(hospitals 1, 2, 3 and 6) it would be best to improve the 
speed of the pathway, for two hospitals (hospitals 4 and 5) 
it would be best to improve the determination of stroke 
onset time, and for one (hospital 7) it would be best to 
judge more patients as eligible for thrombolysis for those 
scanned with time left to treat. Combining all changes 
in the model could produce thrombolysis rates up to 
20%–23%, and 20–23 additional non-disabled outcomes 
per 1000 patients admitted with stroke.
In the case of hospital 5, arrival-to-scan times could be 
slowed by an average of 30 min and clinical outcomes 
would still be greater if that hospital achieved a propor-
tion of known stroke onset time equal to the national 
average.
Clinical decision (machine learning) model
The random forest mode chosen has an 82% accuracy in 
predicting whether a patient received thrombolysis or not 
(see online supplement for more details on validation). 
A machine learning model may be trained on a subset of 
patients to investigate how the difference in thrombolysis 
use between hospitals may be proportionally attributed 
to either the hospital or the local patient population. 
Table 3 shows the predicted use of thrombolysis in a set 
of patients that attend one hospital, based on decisions 
made from training at another hospital. Taking hospital 
7 as an example, between 26% and 45% of the patients 
who currently attend hospital 7 (with time left to receive 
thrombolysis) might receive thrombolysis depending 
on which hospital decision making is used to train the 
model. Patient cohort also affects the predicted throm-
bolysis use. Taking hospital 7 as an example again, if the 
model is trained on decisions made for patients attending 
hospital 7, and different hospital patient groups are then 
analysed in the model, then thrombolysis use is predicted 
to be between 23% and 50% depending on the admitting 
hospital patient group analysed.
Combining pathway simulation and machine learning
The output from machine learning may be incorporated 
into the stroke pathway model by using the machine 
learning model to make the decision in the pathway 
model about whether a patient is ‘judged to be eligible 
for thrombolysis (for patients scanned with 30 min left 
to administer thrombolysis)’. This should tailor the 
clinical decision to the local population, without being 
affected by any particular hospital’s predisposition to use 
thrombolysis. The ‘judged to be eligible for thrombol-
ysis’ parameter in the pathway model may take its value 
from a machine learning model trained using a reference 
set of hospitals. The clinical decision making from these 
reference hospitals may be used to predict which of the 
patients from the hospital under study are eligible for 
thrombolysis.
Table 4 compares base case hospital performance 
(predicted thrombolysis use and clinical benefit) with the 
performance obtainable by a new realistic ‘alternative’ 
practice which is in part informed by the random forest 
machine learning model: (1) the proportion of patients 
with a known stroke onset time is set at the national 
median (67%) unless a hospital is already higher; (2) the 
door-to-needle time is set to 40 min for 90% of patients 
(20 min arrival-to-scan and 20 min scan-to-needle), with 
the other 10% of patients not receiving a scan within 
4 hours of arrival; and (3) the clinical decision to admin-
ister thrombolysis for those patients scanned with 30 min 
left to treat is set by the machine learning model trained 
from a reference hospital (this example uses the hospital 
that has the highest use of thrombolysis for those patients 
scanned with time to treat). Resulting thrombolysis 
targets vary from 16% to 25% depending on the hospital 
(base case 6%–13%).
DISCuSSIOn
While there is no agreed benchmark for the proportion 
of patients with stroke who should receive thrombolysis, it 
has been suggested that about half of patients with stroke, 
if they arrive at hospital in time, could be clinically suitable 
for thrombolysis.18 In practice the greatest proportion of 
patients treated with thrombolysis in English hyperacute 
stroke services is close to 20%.5 These figures contrast 
with an average 12% across England and Wales5 and a 
range of 6%–14% across the seven acute stroke centres in 
our study. Internationally thrombolysis rates also appear 
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Table 4 Combining pathway simulation and machine learning
Hospital
Thrombolysis use (%) Additional good outcomes per 1000 admissions
Current Alternative Current Alternative
1 12.9 (0.3) 18.6 (0.3) 11.3 (0.2) 17.4 (0.3)
2 7.1 (0.2) 15.3 (0.3) 6.1 (0.2) 14.6 (0.3)
3 7.6 (0.2) 22.0 (0.3) 6.3 (0.1) 21.4 (0.3)
4 6.3 (0.2) 17.2 (0.3) 5.5 (0.2) 16.0 (0.3)
5 8.1 (0.3) 25.3 (0.5) 7.1 (0.3) 25.2 (0.5)
6 12.0 (0.4) 23.4 (0.4) 10.5 (0.3) 22.0 (0.4)
7 8.0 (0.2) 16.9 (0.3) 7.1 (0.2) 16.5 (0.3)
Predicted thrombolysis use and clinical benefit (additional good outcomes per 1000 admitted patients) across all modelled hospitals (1–7) 
from the pathway simulation. Data show (base) model based on parameters derived from current performance; alternative ‘realistic target’ 
settings, fixing the proportion of known stroke onset times to the national SSNAP average (67% median) unless the hospital currently 
performs higher, fixing arrival-to-scan and scan-to-needle to 20 min each (with 10% of patients not scanned within 4 hours), and fixing 
the proportion of treatable patients (scanned with 30 min left to treat) according to the output of the machine learning model based on the 
hospital with the maximum predicted proportion given thrombolysis. Data show mean and 95% CI.
SSNAP, Sentinel Stroke National Audit Programme.
on average to be lower than best-practice centres: for 
example, rates have been reported to be 14.6% in the 
Netherlands in 201219 and 5.4% in USA in 201020 (for 
patients aged 65 years or more).
Our pathway simulation model slightly underpredicted 
actual use of thrombolysis. This was mostly due to the 
model applying a strict cut-off of allowable time from 
onset of stroke to giving thrombolysis. In a real clinical 
setting a little bit of flexibility may be applied.
As patients move through the stroke pathway, an 
unknown stroke onset time would be the first key barrier 
to thrombolysis in our model—a barrier to thrombol-
ysis previously noted.21 Although a qualitative analysis of 
methods for determining the onset time of a stroke was 
beyond the scope of this study, it was clear that hospitals 
differed in how this information was gathered, such as 
whether they relied on information from paramedics only 
or whether the hospital clinician would also investigate an 
unknown stroke onset time. In our modelling study we 
looked at the potential impact of reaching the national 
upper quartile for ascertaining stroke onset times. In one 
of the seven hospitals, this factor was the single largest 
in attaining improvements to the thrombolysis rate. For 
patients with unknown time of onset, it may be possible to 
use advanced scanning methods to estimate stroke onset 
times and suitability for treatment21 and further increase 
the population eligible for thrombolysis treatment. As 
advanced imaging techniques become established, the 
model could/should be extended to include this alterna-
tive pathway which our model does not currently include.
Reductions to in-hospital treatment delays have been 
the focus of previous modelling approaches,14 15 and the 
‘need for speed’ has frequently been stressed.11 12 Our 
study found that compared with current state, it was 
reasonable to expect that improvements to pathway speed 
and reliability could achieve close to 50% increase in the 
number of disability-free patients. Our modelling was 
based on consistently achieving 30 min door-to-needle 
times. It may be possible to be even more aggressive on 
process time as speeds of 20 min door-to-needle times 
have been reported.22 Those hospitals in our study where 
paramedics took FAST-positive patients straight to the 
scanner (bypassing emergency department) had signifi-
cantly faster arrival-to-scan times, and this may be a more 
widely applicable approach, although it was not respon-
sible on its own for a higher thrombolysis rate in those 
centres, illustrating the multifactorial influences on both 
thrombolysis rate and door-to-needle time; it may some-
times be best to accept slower pathway speeds in order to 
improve other factors in the pathway (such as ascertaining 
stroke onset time). A challenge for smaller hospitals is to 
have consistently fast processes 24 hours per day, 7 days 
per week; scanners must be rapidly available for patients 
with stroke at any time of day and day of week.
The final hurdle investigated was in the confidence 
in using thrombolysis for patients scanned in time. Use 
of thrombolysis, when time allowed, varied significantly 
between hospitals. Physician uncertainty or lack of confi-
dence in thrombolysis has previously been identified as 
a barrier to use of thrombolysis.23 Despite meta-analysis 
demonstrating the clinical benefit of thrombolysis,10 
the use and benefit of thrombolysis have still recently 
been under scrutiny.24 This could certainly explain the 
large between-hospital variation in thrombolysis rates 
we observed for those patients scanned with time left to 
receive thrombolysis.
Scenarios modelled using our stand-alone pathway 
model used a standard ‘optimum’ rate for the clinical 
decision to use thrombolysis based on an analysis of the 
IST-3 trial. However this scenario assumes all hospitals 
receive patients who have similar characteristics overall 
to those in the IST-3 trial, and assumes that the IST-3 
trial criteria should be a benchmark for all hospitals. The 
machine learning model allows for differences in patient 
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populations between hospitals (eg, reflecting different age 
demographics between different regions) and allows for 
differences in real-life (rather than clinical trial) decision 
making. Using results from the machine learning model, 
which focuses solely on clinical suitability for thrombol-
ysis when there is time left to treat after the scan, enabled 
the pathway model to be refined and tailored further to 
local hospital populations. Machine learning models had 
an accuracy of 80%–82% in predicting decisions made. 
The current performance, while falling short of perfor-
mance necessary for real-world decision making or guid-
ance, is still useful in audit to understand variation in use 
of thrombolysis.
Using machine learning algorithms we found that 
differences in thrombolysis rate, for patients with time left 
to thrombolyse after the scan, can be explained by differ-
ences in patient population and in differences in decision 
making between hospitals. Rather than being based on a 
set of simple rules, our machine learning model learns 
from the clinical decision in real-life settings. A machine 
learning model allows prediction of potential thrombol-
ysis use given the characteristics of the local population, 
but based on real-life clinical decision making at a range 
of hospitals, identifying those hospitals which appear to 
be outliers in their decision making. Bembenek et al18 
have estimated that if the inclusion criteria of the IST-3 
trial are used to determine patients suitable for thrombol-
ysis, about 60% of patients with ischaemic stroke (equiv-
alent to 50% all patients with stroke, if 85% of patients 
have ischaemic stroke) could be suitable for thrombo-
lytic treatment if they arrive in time and the pathway is 
efficient. This overall figure however does not allow for 
differences in patient mix in different geographical areas. 
A clinician reviewing their own use of thrombolysis may 
conclude that their use is different because their patients 
are different. Machine learning confirms differences in 
patient populations, but also suggests differences in clin-
ical decision making. By applying machine learning, feed-
back may be given regarding their use of thrombolysis 
compared with other hospitals, allowing for differences 
in local populations. This may be especially useful if a 
benchmark group of hospitals (acknowledged centres of 
excellence in stroke care) is used to train the model.
When applying ‘stretch targets’ (eg, basing overall 
use of thrombolysis on an analysis of the IST-3 trial) to 
stroke pathways in the pathway model, we found that 
maximum thrombolysis use could be about 20% to 23% 
of all emergency-confirmed stroke admissions. This could 
have the benefit of producing another 20-23 people with 
no significant disability for every 1000 patients admitted 
with confirmed stroke, with potential to also improve 
outcomes for those who cannot be classified as having 
no significant disability even after use of thrombolysis. 
Using slightly less challenging targets for the acute stroke 
pathway process and using machine learning to mimic 
decisions to thrombolyse adjusted for local populations, 
we found that individual hospital targets could realisti-
cally be set in the 16%–25% range, which would lead to 
another 16–25 people with no significant disability for 
every 1000 patients admitted. The upper limit varied 
between hospitals based on the patient mix attending 
that hospital. Such results warn against dangers of setting 
any universal expectation of use of thrombolysis.
This approach has the potential to be applied locally 
or, as it is based solely on SSNAP data, as part of the 
national audit of stroke services. The methods have the 
potential to be automated, allowing for incorporation 
into the quarterly stroke service audit conducted by 
SSNAP. Where clinical decision making appears to be 
significantly different from a reference group of hospital, 
the machine learning model may be used to identify a 
small group of patients for review, where clinical decision 
making appears to be different from a model trained on 
an agreed benchmark set of hospitals.
Our work is not the first work to apply simulation or 
machine learning in stroke. Previous work has been 
published on using pathway simulation at an individual 
hospital level.14 15 We build on previous work by using 
standardised data and an open simulation framework to 
enable pathway simulation to be performed at scale across 
all hospitals covered by the national stroke audit. Previous 
work has also been published using machine learning to 
predict risk of stroke25 and likely outcome.26–28 Where our 
work adds novelty is first in the combination with pathway 
simulation and the use of machine learning to investigate 
differences in clinical decision making between hospitals, 
and to apply ‘what if?’ scenario testing of what might the 
likely clinical benefit be of standardising clinical decision 
making in accordance with recognised centres of excel-
lence, taking into account differences in local patient 
populations.
Strengths and weaknesses
A key strength of our study is that, since the models are 
based solely on SSNAP data, the models developed may 
be applied to all UK hospitals. The use of open source 
software and the provision of our code in a public repos-
itory should also facilitate easier adoption. Monks et al29 
have noted that when modelling stroke pathways, the 
level of detail of the model should depend on the ques-
tions being addressed. In our approach we consciously 
limit ourselves to the detail found in SSNAP data. A weak-
ness, therefore, is that the models as they are presented 
cannot address questions that require data outside of the 
SSNAP data set. Our models highlight the improvements 
that can be achieved by an overall pathway stage (such as 
arrival-to-scan) but do not inform how improvement in 
that step could/should be achieved.
A strength of our modelling compared with normal 
approaches to stroke pathway modelling29 is that we have 
used machine learning in order to both allow for differ-
ences in local stroke patient populations (eg, differences 
in age, gender and severity) and to understand differences 
in decision making between hospitals. A limitation of this 
approach is that the modelling is limited to hospital level 
and will not uncover differences in use of thrombolysis 
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by different practitioners within the same hospital. Never-
theless, the model will pick up overall organisational 
cultural attitudes towards use of thrombolysis in stroke 
(such as whether one hospital is more or less likely to use 
thrombolysis for patients with less severe stroke).
The use of open source software and the provision 
of our code in a public repository should also facilitate 
easier adoption or refinement of the approach by others.
A weakness of this study is that it was limited in scope 
to seven hospitals. This methodology should preferably 
be validated on a larger data set (eg, the national SSNAP 
data set).
Our model is deliberately limited to the SSNAP data 
set, as that is universally available across all stroke units 
in England and Wales. There are likely useful clinical 
features missing from the SSNAP data set (eg, information 
from advanced imaging). As the SSNAP data set grows, 
we would expect accuracy of the machine learning model 
to increase beyond the current 80%, but we believe the 
model is already sufficiently useful to add more insight 
into the routine SSNAP audit.
In this model we have considered only use of throm-
bolysis. As the SSNAP data set grows, we would expect 
a similar approach to be useful in identifying levels to 
increase use and speed of thrombectomy (by introducing 
interhospital transfer, when required, into the clinical 
pathway model, and also building a learning model on 
use of thrombectomy to identify differences in selection 
of patients for thrombectomy). Additionally, we have 
focused on the most usual path to thrombolysis—those 
arriving and scanned with time left to treat within the 
normal thrombolysis time limits. Advanced imaging may 
be used to select further patients30; as advanced imaging 
becomes more commonplace, then the model would be 
best extended to include this additional pathway.
In this study we have not focused on how implemen-
tation of changes may be brought about in different 
hospitals. It is possible that some improvements in the 
pathway (such as rapid availability to scan 24/7) may only 
be possible by centralisation of services into larger units 
who may have more resources to deploy.31–33 Our model 
will show the benefit of reducing pathway speed and vari-
ability, but does not imply such a change is necessary and 
always possible in smaller hospitals.
COnCluSIOnS
The stroke clinical audit reports on thrombolysis usage 
(percentage of patients receiving thrombolysis) and time 
to thrombolysis. Interhospital variation in use of throm-
bolysis may be due to (1) differences in stroke pathway, 
(2) differences in patient population characteristics 
or (3) differences in clinical decision making. In our 
study we present a method that qualitatively analyses 
key components of the stroke pathway in a manner that 
may be applied at scale while producing individualised 
results for each hospital, highlighting how thrombolysis 
use and speed may best be improved. We believe this type 
of approach will augment current outputs from national 
clinical audits.
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